B of A Securities Maintains Buy on Lyra Therapeutics, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Gerberry maintains a Buy rating on Lyra Therapeutics (NASDAQ:LYRA) and raises the price target from $13 to $15.
September 12, 2023 | 2:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lyra Therapeutics' price target has been raised from $13 to $15 by B of A Securities, which maintains a Buy rating on the stock.
The raised price target and maintained Buy rating by B of A Securities indicates a positive outlook for Lyra Therapeutics. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100